A simple and flexible setup for conducting drug metabolism studies is described in this report. A heating block was designed for the Multimek liquid handler platform for incubation of multiple samples at 37°C in a 96-well format. This setup enables the rapid performance of drug metabolism experiments on a large number of samples. In this report, the authors present the validation of the system by 1) showing reproducible and consistent determination of the in vitro half-life of midazolam in every well across the entire plate and 2) determination of metabolic parameter values of midazolam, testosterone, diclofenac, warfarin, and dextromethorphan and inhibition parameter values of quinidine and ketoconazole, all comparable to literature values. In addition, the authors demonstrate the application of the setup to determining the metabolic stability of a set of proprietary compounds, the inhibition of activity of cytochrome P450 (CYP) enzymes, and the conduct of a single combination experiment that can simultaneously determine the metabolic stability and CYP inhibition activity. Overall, the system represents a simple, high-throughput and useful tool for drug metabolism screening in drug discovery. (Journal of Biomolecular Screening 2003:544-554) 
INTRODUCTION
I N DRUG DISCOVERY, high-throughput screening (HTS) assays provide low-resolution data for preliminary assessment of the desired properties of the compounds. One of the properties-interaction with the liver enzymes, mainly the cytochrome P450s (CYP)-has become as important for the preliminary assessment of the compounds as assessing their selectivity and sensitivity toward the target. It is a liability if a compound is rapidly metabolized or is an inhibitor of the enzymes, and knowledge of these liabilities early in a drug discovery program can be used to either rectify the problem or eliminate a compound from development. Thus, there is a continuing effort to devise ways to assess these properties rapidly and in valid experimental setups.
Various attempts have been made to increase the throughput of these assays. For example, fluorescence-based assays for determining the inhibition of CYP activity are available for a number of isozymes and are being used in HTS of small molecules. 1 In these assays, the nonfluorescent substrate, upon enzymatic conversion, generates a fluorescent metabolite that is detected in a fluorescence plate reader. The assay is often performed at ambient temperature with single endpoint measurement of the reaction to make it easy to adapt to robotic systems. This method can be applied to determining IC 50 values, although at a relatively low throughput. The most serious drawback of this method is the interference from the intrinsic fluorescence or possible fluorescence-quenching effects of compounds with the detection of substrate metabolite. Another issue is that the nonfluorescent substrates that convert into sensitive fluorescent metabolites are not available for all isozymes. These compounds also lack the required specificity as substrates for these enzymes, hence cannot be used with human liver microsomes but have to be used with individually expressed CYP enzymes. An LC-MS method with specific drug probes will overcome many of these limitations if it can provide sufficient throughput and flexibility.
Until recently, knowledge of whether the compound itself is a substrate of the enzyme was not sought in early stages of discovery. The pathway of metabolism of the compound and the identification of the metabolite(s) were determined for smaller numbers of compounds in preparation for in vivo pharmacokinetic studies. The main reason for the postponement of these tests until later was that they required high-resolution data. The chromatographic separation of the parent compound and the metabolites was needed for their detection and quantitation by ultraviolet, fluorimetric, and mass spectrometric methods. Furthermore, the instrumentation for generating samples in high-throughput enzyme kinetics assays was not available, particularly for performing assays at physiological temperature. Even now, very few systems for kinetic studies are available for automated low-to medium-throughput sample generation. They are expensive to purchase and maintain and require considerable time for personnel training.
For these reasons, there is a quest for better systems and methods that can be used to assess these properties in drug discovery support. Here we describe a simple system that is used in performing a variety of assays on compounds from determining the rate of reaction to screening a full plate of compounds for in vitro half-life measurements and determining the level of CYP inhibition. We have used ballistic gradient liquid chromatography and mass spectrometry for detection of the parent ion and the metabolite(s). Mass-spectrometric (MS) analysis using single ion monitoring provided high sensitivity and eliminated the need for long gradient for the resolution of the peaks during liquid chromatography. A generic ballistic gradient program was used for the chromatography of all compounds with conditions for the MS detection optimized for each. Thus, the sample analysis time was shortened considerably increasing the overall throughput of the method. Inhibition constant (K i ) and the Michaelis constant (K m ) of known inhibitors and substrates, respectively, were determined using the same setup to confirm its validity.
MATERIALS AND METHODS

Reagents and supplies
The recombinant human CYP450 2C9, 2D6, and 3A4 were from Gentest (cat. #456258, 456217, and 456202, respectively). NADPH, sodium phosphate (di-and mono-basic), commercially available inhibitors, and substrates and their metabolites were from Sigma or Gentest. The substrates and the metabolite pairs used in this study were the following: midazolam and 1′-hydroxymidazolam, testosterone and 6β-hydroxytestosterone, S-(-)-warfarin and 7-hydroxywarfarin, dextromethorphan and dextrorphan, and diclofenac and 4′-hydroxydiclofenac. Acetonitrile and DMSO were of analytical reagent grade. The 1-ml deep-well polypropylene assay plates were from Greiner (Masterblock™, cat. #780 201), and the deep-well polypropylene sample plates for submitting samples for analysis were from Beckman (cat. #267006). Shallow-well polypropylene plates with pierceable covers were from Microliter Analytical Supplies (cat. #07-1200 and 07-0011N) and were used later instead of the deep-well polypropylene sample plates. The 96-well PCR plates (cat. #TECAB-0600, DIAMED) were used for incubation of the samples when lower volumes were required for a single time-point measurement. A temperature-controlled plate centrifuge was used for centrifugation of the samples and was from Beckman. The Multimek (Beckman) was fitted with the P200 head for 96 tips.
The heating block was custom-made by HyperTask™ for the Multimek liquid handler. It was designed to be used at the distal end position (position 6) on the Multimek deck. This position was the least intrusive for the configuration of the remaining stations on the Multimek. The coordinates for positioning the heating block on the Multimek deck are precise for the programming of the tip head. The walls of the heating block are hollow, and the inlet and the outlet on the heating block are connected to a circulating water bath maintained at 37°C for heating the walls of the chamber. The outer walls are insulated to prevent heat loss, and the walls of the chamber are anodized to prevent rusting. The chamber is filled with water to provide good contact for the uniform heating of every well of the plate. This design minimizes the possibility of accidental flooding on the Multimek because there is no circulating water in the chamber. The Masterblock™ plate fits into the heating block and is held in position with 4 screws. For the PCR plate, a removable adapter was designed to fit in the heating block and hold the plate in position. The 4-deck platform was used to position reservoirs, plates for reagents, and the plates for sample transfer. The setup is shown in Figure 1 .
The design of the incubation chamber in the system described required a plate that can be fitted into the chamber with the warm water surrounding each and every well to the same height. Several deep-well polypropylene plates were tested in the heating block. With almost all plates, an air pocket formed underneath the top plastic, preventing the water level from reaching near the top of the well and causing the plate to float. Only the Masterblock™ plate Multimek with the heating block. The heating block is configured directly on the Multimek deck next to the tip-box carriage. The 4-deck platform is used for the plates and reservoirs. The tubing for circulating the heated water in the walls of the heating block is connected to a circulating water bath and is not visible in this photograph. The deep-well reaction plate is shown in the heating block.
from Greiner was found suitable because it does not have a continuous layer of plastic at the top of the plate. Instead, each well is a separate tube connected only tangentially with the neighboring tubes, leaving open spaces between every well. This design allowed the water level to reach near the top of the wells, ensuring uniform and even heating of every well on the plate.
For small reaction volumes, the PCR plate was used in the same heating block. An adaptor with walls slightly lower in height compared to the walls of the heating block was placed inside the chamber on which the PCR plate could be gently floated without trapping any air bubbles underneath the plastic layer. The size of the adaptor was designed to fit the plate precisely to hold it in position. The X, Y, and Z coordinates for the Multimek head were readjusted for this setup. The preincubation time was also shortened because the thin walls of the PCR plate allowed the smaller volume in the reaction mixture to thermally equilibrate much faster.
Preparation of assay solutions
Sodium phosphate, 0.1 M, pH 7.4, was prepared from Na-phosphate, dibasic and Na-phosphate, monobasic in distilled water. The NADPH solution (20×) was prepared fresh by adding 1.09 ml of cold buffer to each 5-mg vial. The 10× enzyme solution was prepared by thawing the stock (1 µM) at 37°C and diluting in cold buffer to the desired concentration. Stock solutions of substrates, inhibitors, and test compounds were prepared in DMSO and stored at 4°C. The compounds were diluted to 100× in an acetonitrile:water mix (1:1, v/v). The stop solution was 100% acetonitrile. In later experiments, 0.33 µM warfarin was added to the acetonitrile as the internal standard. Prior to the sample generation, the test compounds were diluted to 100 µM in 80% acetonitrile for bioanalytical method development. For K m measurements of known substrates, analytical conditions for the detection of the known metabolites were also optimized. The standard solutions of the known metabolites were prepared for quantitation where necessary.
Sample generation and analysis
The procedure for sample generation and sample analysis by LC-MS for various types of experiments is given below, with a step-by-step description of the method elaborated in the first example.
Validation
For the validation of the system, midazolam was used as a test compound in all 96 wells, and samples were generated at 6 time points for analysis. The Beckman deep-well plates were labeled for the various time points (0, 3, 6, 10, 15, and 30 min) indicating the time of reaction termination. Three V-bottom shallow-well plates were labeled "COMPOUND," "ENZYME," and "NADPH." The 100× test compounds (50 µl), 10× enzyme (110 µl), and 20× NADPH (70 µl) were pipeted into the wells of the respective plates. These transfers were performed either manu-ally using a multichannel pipettor or with the Biomek immediately before the start of the experiment. The final concentrations of the reagents in 850 µl reaction volume were as follows: 100 mM Naphosphate, pH 7.4, 275 µM NADPH, 0.5 µM midazolam, and 10 nM enzyme unless otherwise noted.
The Multimek was programmed for liquid transfer for the steps described below and in the order they were performed. Liquid transfer to a maximum of 3 plates can be performed because the remaining 3 stations are for the heating block, tip box (each at a fixed position), and reagent reservoir. 1 . The stop solution (150 µl) was added to 6 deep-well plates labeled with time points. The plates were covered with plastic mats and set aside. 2. Buffer (4 × 178.5, 714 µl total) was added to the incubation plate in the heating block and heated for 5 min. 3. The enzyme (85 µl) and the compounds (8.5 µl) were aspirated sequentially and delivered to the incubation plate after 5 min. Samples were mixed by aspiration/dispensation 3 times at a low speed and heated for 10 min. 4. Of the reaction mix, 95 µl were removed into the 0-min plate containing the stop solution. The contents were mixed by aspiration/ dispensation 3 times at a regular speed. 5. NADPH (37.5 µl) was added to the incubation plate to start the reaction. 6. Samples of 100 µl were removed at 2.5, 5.5, 9.5, 14.5, and 29.5 min into the plates containing the stop solution for 3, 6, 10, 15, and 30 min, respectively, as described above. 7. NADPH (5 µl) was added to the 0-min plate.
At each step, new tips were used to prevent contamination of the samples. After stopping the reaction, the plates were covered with plastic mats and centrifuged for 15 min at 3200 rpm and 25°C
. The supernatant (175 µl) was transferred into fresh deep-well or the shallow-well plates using the Multimek. The plates were covered with the pierceable plastic mats and were loaded on the deck of a Gilson autosampler for analysis by the LC-MS. Blank solution containing the enzyme, NADPH, stop solution, and buffer was prepared in 15-ml conical tubes and centrifuged similarly. Of the supernatant, 175 µl was transferred into the wells of a polypropylene plate and used for the injection of blank samples during the LC-MS analysis. Approximately 600 samples per plate are generated from 1 experiment for analysis.
For sample analysis, optimized conditions for the detection of the parent ion were used as determined from the automated method development for midazolam. Samples were injected from the expected low to high amount (for example, 30 min to 0 min) of parent ion to prevent artifacts due to carryover. The blank samples were injected before and after each series of samples. The flowrate was 1.0 ml/min, and the injection volume was 5 µl. The solvents for the gradient were as follows: solvent A: 100% HPLCgrade water + 0.1% formic acid + 0.1% isopropanol; solvent B: 100% HPLC grade acetonitrile + 0.1% formic acid + 0.1% isopropanol by volume. Ace C8 (2 × 1 mm ID) or Polymerix RP-1 (4 × 2 mm ID) columns were used for chromatographic resolution with ballistic gradient over 0.5 min with 0.5-min hold and 0.05min ramp. The total run time was 1.2 min. A Sciex API-4000 was used for MS/MS analysis. The internal standard warfarin, when present, was monitored with the analyte(s).
Half-life (t 1/2 ) measurement
The system described above was used for determining the t 1/2 of 80 proprietary compounds. The compounds were plated in columns 2 through 11 of the 96-well plate. A known substrate of the enzyme was placed in well A1 for the positive control. For sample analysis, optimized conditions for the detection of the parent ion were used as determined from the automated method development for each compound. The blank samples were injected before and after a series of samples of each compound. The chromatographic conditions for sample analysis were the same as described above for all compounds.
Inhibition/turnover measurement
On the COMPOUND plate, the known substrate of the enzyme was added to each compound in columns 2 through 11. Column 1 contained the substrate without the compounds, and in column 12, 4 concentrations (close to the K i concentration) of a known inhibitor were mixed with the substrate in different wells. The substrate concentration was close to the K m , and the compounds were at 2 µM in the final mixture. The substrate, inhibitor, and the compounds were at 100-fold of the final concentration in the reaction and were diluted in acetonitrile/water (1:1, v/v). All ingredients in the reaction were added to the reaction plate as described above using the same sequence of addition and the same volumes. The sample generation was as described above. Conditions for sample analysis were similar to the ones described above with the following changes: Four ions were monitored simultaneously in this experiment-ions for substrate, compound, the metabolite of the substrate, and the internal standard.
K m measurement
The COMPOUND plate contained varying concentrations of the substrate in these experiments. Depending on the requirements, samples could be prepared in duplicates or triplicates, and multiple substrates could be assayed in a single setup. Samples can be generated for either a single time-point measurement or the multiple time points as described above. For the single time-point measurements, a PCR plate was used in the heating block. The Multimek program was modified to accommodate the changes in the height of the tips for the PCR plate and smaller volumes (200 µl total) used for the reaction. The sample generation was as described above. The standard solutions of the metabolite were prepared in the blank solution for quantitation on a separate plate. Conditions for sample analysis were as described. Both substrate ion and the metabolite ion were monitored for these experiments.
The COMPOUND plate contained varying concentrations of the substrate and the inhibitor at 100-fold of the final assay concen-tration. Multiple enzyme concentrations could be used on the enzyme plate. Samples could be generated for either a single timepoint measurement or the multiple time points as described above. The reaction was terminated by addition of one-fifth volume of acetonitrile containing the internal standard, and the samples were analyzed without further purification. Both substrate ion and the metabolite ion were monitored together with the internal standard using the conditions for chromatography and detection as described above.
Data analysis
Peak areas of the analytes were normalized against the internal standard when it was used in the experiment, and data analysis was performed using peak areas or area ratios. Data manipulation was performed in Excel and curve fitting and parameter estimations in GraphPad PRISM™. Further manipulation of the data for calculating various kinetic parameters is described below.
Half-life (t 1/2 ) measurement
The percentage of parent ion remaining in the sample relative to the 0-min sample was calculated for each compound at each time point. The data were fitted in the PRISM™ program using nonlinear regression analysis for one phase exponential decay for calculating the half-life (t 1/2 ).
Measurement of Michaelis constant (K m )
Standard solutions of the known substrates and their metabolites were prepared to generate standard curves for estimation of analytes' concentrations. The rate of metabolite formation (v) was plotted against the substrate concentration [S]. The data were fitted in the PRISM™ program using nonlinear regression analysis for one-site binding for calculating the K m .
Determination of the inhibition constant (K i )
Standard curves of the substrates and their metabolites were prepared for estimation of analytes' concentration. Peak areas were normalized against the internal standard for the substrate and the metabolite. The rate of metabolite formation (v) was plotted against the substrate concentration [S] at each inhibitor concentration. The K m values were determined as described above at each inhibitor concentration. The plot of the observed K m versus inhibitor concentration [I] was made to determine the K i using linear-regression analysis.
RESULTS AND DISCUSSION
Experimental design
The requirement and use of ADME data have become an integral part of the drug discovery process. Evaluation and progression of compounds along the discovery process and into the development phase now require that the compounds have the appropriate ADME profiles for the intended use. Consequently, the need for
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generating good-quality ADME data on which decisions will be made and at a throughput that is compatible with the pace and turnaround time required in drug discovery has greatly increased. Recent advances in methodologies have produced some improvements, but most still do not have the required throughput or provide data only of low resolution.
This study presents the development and validation of a system that affords the flexibility to generate in-depth high-quality data and can also be used for high-throughput data generation. This has been achieved with the design of a heating block that can be used for the incubation of compounds in a 96-well format onto the platform deck of a Beckman Multimek liquid handler. The proximity of this heating block to the other positions on the deck where reagents and sample containers are located makes it much more feasible to conduct experiments that require sampling over short intervals of time, some as short as 2 to 3 min, as was the case for some experiments reported here. This is a definite advantage over many HTS instruments with incubators/hotels for plates, where the logistics and manipulations required for adding reagents and sampling unavoidably result in extended incubation periods. These instruments are unsuitable for detailed studies requiring sampling over short intervals of time to characterize the kinetics of a process or reaction.
Method validation
Because there is no provision for stirring the samples during incubation, the settling of the Supersomes™ to the bottom of the well and creating a nonuniform environment during the course of the reaction was of concern. As we have demonstrated in this report, this did not have an adverse effect on the quality of the data. Such a phenomenon would have been expected to produce a high degree of variability in the data. However, as demonstrated by the data generated when midazolam was incubated in every well, the results obtained across the entire plate were comparable, even with low interoperator variability ( Table 1 ). The individual data plots from each well are shown in Figure 2 , and they show the consistency of the data across the entire plate. The calculated elimination half-life values were compared across columns and rows and for 2 independent operators ( Table 1 ). The numbers across the plate and between operators are comparable. The robustness of the setup is further demonstrated by the statistics on the substrates used as controls in the screening of the compounds from 3 different projects ( Table 2 ). The higher standard deviation in substrate 3 over a 20mo period is partly due to multiple batches of the enzyme.
K m measurements
As further evidence of reliability and validation of the system, the K m values for various selective probes of 3 of the major CYP enzymes in humans were determined. Testosterone and midazolam were used as substrates for 3A4, diclofenac and warfarin for 2C9, and dextromethorphan for 2D6. The results from these experiments and the literature values are shown in Table 3 for comparison. These results are in good agreement with published values [2] [3] [4] [5] [6] and are comparable to previously reported values obtained by traditional methods.
Half-life (t 1/2 ) measurements
Apart from demonstrating the validity of the system, its application to support drug discovery projects was also examined. The metabolic stability of compounds was assessed by determining the in vitro half-lives in the presence of the CYP enzymes. The lability Saraswat et al. of 80 proprietary compounds in the presence of CYP 3A4, 2C9, and 2D6 was determined using this system. A compound from an internal project was used as control because midazolam could not be used as the reference compound due to the decreased half-life at higher enzyme concentration. The known substrates, diclofenac and dextromethorphan, were used as reference compounds for CYP 2C9 and 2D6, respectively. The calculated half-life values from these experiments are shown in Table 4 . The r 2 value was >0.5 for all t 1/2 values reported. The t 1/2 values were not reported when 1) r 2 values were <0.5 due to a scatter in the data (ds), 2) no decay of the parent ion was observed (id), or 3) data were missing due to instrument error (ie). The missing values on some compounds were due to the lack of signal after the 0-min time-point samples, indicating that the compounds were extremely labile in that assay (rm). From the half-life values, most compounds on this plate appeared to be substrates for CYP 3A4, as was the reference compound with a t 1/2 of 11 min. The substrate for 2C9, diclofenac, decayed with a half-life of~8 min under the assay conditions. Most of the 80 compounds showed limited or no metabolism in the presence of CYP 2C9, and half-life values could not be determined. Therefore, these compounds are stable in the presence of CYP 2C9. Dextromethorphan decayed very rapidly under the assay conditions for CYP 2D6, with a half-life of <2 min. There were a number of compounds that were labile in the presence of CYP 2D6 as well as some that were stable and did not show any decay of the parent ion intensity. The t 1/2 values for a large number of compounds (16%) could not be calculated due to the rapid decay of the parent ion in the presence of CYP 2D6.
By comparing the results from different enzymes, the compounds appear to be mostly substrates for CYP 3A4 because the metabolic half-life was below 10 min. By contrast, with CYP 2C9, most of the compounds were not metabolized at all, and half-life estimates could not be obtained for them. CYP 2D6 showed capability to metabolize many of the compounds but not as many as CYP 3A4. These expressed enzymes could easily be replaced with liver microsomes, which are more commonly used for metabolic stability assessment.
Inhibition/turnover measurements
The possibility of obtaining more information from a single experiment was explored in another set of studies in which the halflifes of the compounds were determined in the presence of a known substrate of the enzyme. If a compound is an inhibitor of the enzymatic activity, the substrate metabolism will be affected, and it would be reflected in the decay pattern of the substrate and the appearance of its metabolite. This was explored with a known enzyme (CYP 2D6), substrate (dextromethorphan), and inhibitor (quinidine) combination. Figure 3 shows the data plots from the substrate, in the absence and in the presence of various concentrations of the inhibitor. The effect of the inhibitor was demonstrated both with the disappearance of the parent substrate (Fig. 3A) and appearance of the metabolite (Fig. 3B ). The substrate depletion was rapid in the absence of the inhibitor as observed n the previous experiment. As expected, with increasing concentrations of inhibitor, there was reduction in the disappearance rate of parent substrate (increased half-life) and reduction in rate of metabolite formation.
Using a similar approach but different proprietary compounds, the ability of various compounds to inhibit the activity of an enzyme and their metabolic stability can be easily assessed and compared. To demonstrate that, data were obtained in the presence of different proprietary compounds. The substrate metabolism was very rapid in the absence of any compound (t 1/2 of <1 min) and decreased to different extents in the presence of compounds presumably through affecting the enzymatic activity to various degrees (Fig. 4 , Table 5 ). The elimination of the proprietary compounds was also monitored. The time profile of all 3 analytes simultaneously are plotted for a select group of compounds in Figure 4 , showing the disappearance of substrate, appearance of the corresponding metabolite, and disappearance of the compound. These plots clearly illustrate if the compound is a substrate and/or an inhibitor. For example, compounds 1, 4, and 5 had very short halflives (t 1/2 < 3 min; Table 5 ), indicating that these are substrates for 2D6, whereas compounds 2 and 3 were found to be stable. However, these 2 stable compounds affected the substrate metabolism differently. Compound 3 showed very similar substrate metabolism (t 1/2~2 min) to that observed with very labile compounds, but compound 2 inhibited both substrate metabolism and the appearance of its metabolite significantly. The effect on the rate of appearance of the substrate metabolite in compounds 2, 3, and 4 is different, indicating that the mechanism of action is potentially different for these compounds. This further illustrates that useful insights can be obtained on drug-drug interaction by detailed studies on the compounds of interest using this approach.
K i measurements
In addition, we determined the inhibition constant (K i ) of known inhibitors of some of the major human CYP enzymes. Figure 5 shows the experiments for CYP 3A4 and 2D6 using midazolam and dextromethorphan as substrates, respectively. As The metabolite monitored for each substrate is shown. The reaction was terminated at 2 to 5 min in all cases except warfarin, in which the reaction time was 30 min. The in-house values are averages of 2 measurements, with the standard deviation indicated in parentheses.
expected, the rate of metabolite formation decreased and the K m increased with increasing concentration of the inhibitor. The K i values for ketoconazole and quinidine as determined from the plots were 0.69 µM (±0.07 µM) and 8.4 nM (±1.4 nM), respectively. These values are in general agreement with the values reported in the literature. [7] [8] [9] These examples demonstrate the utility of the system for detailed kinetic studies, for example, estimation of inhibition constants, or to screen a large number of compounds by a highthroughput method made possible by the feasibility for frequent sampling required for kinetic work. One of the major features that confer flexibility to the system is the ability to have compounds and reagents in a well format rather than in reservoirs. Thus, it is possible to have different experimental designs (e.g., multiple enzyme, substrate, and inhibitor concentrations), different combinations in different wells, or use the same combinations or concentrations to screen a larger number of compounds. One of the consequences of this setup is that irrespective of which experimental design is being used, large numbers of assay points are generated for high-resolution data. In the cases reported here, about 600 assay points were produced from each experiment. This requires adequate sample processing to prevent any breakdown in the system, for example, protein precipitation is required to avoid backpressure buildup on the LC column. Several methods were investigated for removing the protein from the samples to avoid this phenomenon. The solid-phase extraction in a 96-well plate was tested using the filtration method. The sample recovery varied and was dependent on the properties of the compound (data not shown). Experiments using various volumes of methanol and acetonitrile for precipitating the protein were also conducted. Acetonitrile (1.5 volumes) was best suited to precipitate most of the protein from the solution, which could then be pelleted by centrifugation. Clear supernatants were transferred to new plates to avoid any possibility of column clogging due to the resuspension of the pellet over the course of several hours of sample analysis. The described system and method provides the potential for rapid results generation. It takes between 2 and 3 h to process samples equivalent to a full plate of compounds. Currently, the limitation is in the bioanalytical area, where 16 to 20 h are re-quired for the analysis of large set of samples generated, even with ballistic gradient method and short run time. Overnight and unattended operation clearly facilitates efficient use of time. Although not explored in this study, it may also be possible to use the system for other types of studies. The system could be configured to conduct experiments for reaction phenotyping and, because the reaction volume can easily be increased to 1 ml with the plates used, also for metabolite identification experiments.
CONCLUSION
A high-throughput system for conducting enzyme kinetics experiments has been developed and validated. It has an advantage over some of the currently available systems because of its simplicity, relative lower set-up cost, and flexibility. This allows adaptation of the system for detailed kinetic studies or HTS without major changes in setup or format. The validity of the system was demonstrated through determination of metabolic and inhibition parameters for known substrates and inhibitors, which were comparable to literature values. Its utility was demonstrated through the generation of metabolic stability and/or inhibition potential data on a set or proprietary compounds. Overall, it provides a useful tool for the drug metabolism laboratory that can facilitate the process of adequately supporting drug discovery with in-depth, high-resolution data and high-throughput approaches.
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